期刊
CANCER RESEARCH
卷 71, 期 6, 页码 2118-2128出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-10-2426
关键词
-
类别
资金
- NCI [CA125387]
- Greater Milwaukee Foundation
- Canadian Institutes of Health Research (CIHR)
- Canadian Breast Cancer Research Alliance (CBCRA)
- Uehara Memorial Foundation
- Grants-in-Aid for Scientific Research [21790340] Funding Source: KAKEN
Breast cancers with estrogen receptor alpha (ER alpha) expression are often more differentiated histologically than ER alpha-negative tumors, but the reasons for this difference are poorly understood. One possible explanation is that transcriptional cofactors associated with ER alpha determine the expression of genes which promote a more differentiated phenotype. In this study, we identify one such cofactor as coactivator-associated arginine methyltransferase 1 (CARM1), a unique coactivator of ER alpha that can simultaneously block cell proliferation and induce differentiation through global regulation of ER alpha-regulated genes. CARM1 was evidenced as an ER alpha coactivator in cell-based assays, gene expression microarrays, and mouse xenograft models. In human breast tumors, CARM1 expression positively correlated with ER alpha levels in ER-positive tumors but was inversely correlated with tumor grade. Our findings suggest that coexpression of CARM1 and ER alpha may provide a better biomarker of well-differentiated breast cancer. Furthermore, our findings define an important functional role of this histone arginine methyltransferase in reprogramming ER alpha-regulated cellular processes, implicating CARM1 as a putative epigenetic target in ER-positive breast cancers. Cancer Res; 71(6); 2118-28. (C) 2011 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据